Figures show 28% of 111 UK patient groups have a positive impression of pharma firms, attributable to 81% of groups partnering with them, compared to the global figure of only 43%, according to a report by PatientView. The participants criticised the sector for a lack of transparency surrounding pricing policies, clinical data sharing and the funding of external stakeholders, and called for a more patient-centric approach.
Figures show 28% of 111 UK patient groups have a positive impression of pharma firms, attributable to only 43% of groups partnering with them, compared to the global figure of 81%, according to a report by PatientView. The participants criticised the sector for a lack of transparency surrounding pricing policies, clinical data sharing and the funding of external stakeholders, and called for a more patient-centric approach.